ArticleDiscover oncology2025
CircFAT1(e2) acts as a sponge for miR-30e-5p and inhibits glioma progression by regulating MYBL2-mediated cell proliferation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGliomas present formidable challenges due to their aggressive nature and limited treatment efficacy. This study examines the roles of circFAT1(e2) and the MYB gene family, particularly MYBL2, in glioma etiology. MATERIALS AND
methodsFunctional experiments were conducted to investigate the impact of MYBL2 on glioma cell behavior. Techniques such as quantitative polymerase chain reaction (qPCR), Western blotting (WB), Flow cytometry assays, cell counting Kit-8 (CCK-8), Transwell assays, colony formation assays as well as in vivo tumor growth were employed. Additionally, luciferase assays and RNA interference techniques were employed to investigate the regulatory relationship between miR-30e-5p, MYBL2, and circFAT1 (e2).
resultsDifferent expression patterns of the MYB gene family were observed in glioma subtypes, with MYBL2 emerging as a predictive biomarker. A nomogram combining MYBL2 expression and patient age predicted survival, negatively correlating with increased MYBL2 expression. MYBL2 knockdown affects glioma cell migration, invasion, and proliferation, suggesting its tumorigenic role. miR-30e-5p was identified as a direct regulator of MYBL2, decreasing its levels and suppressing glioma growth upon overexpression. Additionally, circFAT1(e2) was found to be predominantly cytoplasmic, resistant to RNase R, and stable as circular RNA. Silencing circFAT1(e2) reduced glioma growth and metastasis, inducing G1 phase cell cycle arrest. Conversely, circFAT1(e2) overexpression countered apoptosis induced by miR-30e-5p mimics.
conclusionsThis study unveils a regulatory axis involving miR-30e-5p, circFAT1(e2), and MYBL2, offering potential therapeutic targets for glioma treatment and shedding light on its molecular complexity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.